IFN-β treatment also significantly decreases IL-1β, NLRP3 and AIM2 expression in MS patients, suggesting that IFN-β might improve MS symptoms by decreasing inflammasome-dependent IL-1β production. Here, AIM2 is linked to myeloid sarcoma.